http://www.tvm-capital.com Current news from TVM Capital and portfolio companies in life sciences and technology de Sat, 04 Jul 2009 11:22:10 GMT Sat, 04 Jul 2009 11:22:10 GMT TVM Capital webmaster@tvm-capital.com Copyright © 2008 by TVM Capital Subscribe with My Yahoo!Subscribe with NewsGatorSubscribe with My AOLSubscribe with BloglinesSubscribe with NetvibesSubscribe with GoogleSubscribe with Pageflakes http://feedproxy.google.com/~r/tvmcapitalallnews/~3/77fPemfO5R0/inv0701e.php New York, NY / Kissing, Germany � July 1, 2009 � invendo medical Inc., developer of a novel single use and potentially sedation- and painless colonoscope, announced that it has appointed John J. Cifarelli as Executive Vice President Global Markets. He will join as a member of invendo�s Executive Committee. Berthold Hackl, CEO of invendo medical, said, �We are excited and extremely pleased that John is joining our team. He brings very deep and valuable knowledge of the medical endoscope... Wed, 01 Jul 2009 14:31:00 GMT http://www.tvm-capital.com/pages/news/2009/inv0701e.php http://www.tvm-capital.com/pages/news/2009/inv0701e.php http://feedproxy.google.com/~r/tvmcapitalallnews/~3/dHJvK4iUN9Q/inv0701d.php New York, NY / Kissing, Deutschland � 1. Juli 2009 � invendo medical Inc., Entwickler eines neuartigen und potentiell sedierungs- und schmerzarmen Einmalkoloskops, gab heute die Bestellung von John J. Cifarelli als Executive Vice President Global Markets bekannt. Er wird Mitglied von invendos Executive Committee. Berthold Hackl, CEO von invendo medical, kommentierte, �Wir sind begeistert und freuen uns sehr, da� John unser Team erweitert. Er verf�gt �ber sehr umfangreiches und wertvolles... Wed, 01 Jul 2009 14:29:00 GMT http://www.tvm-capital.com/pages/news/2009/inv0701d.php http://www.tvm-capital.com/pages/news/2009/inv0701d.php http://feedproxy.google.com/~r/tvmcapitalallnews/~3/m71gyDcl1WY/ark0701.php London, UK, 1 July 2009 - Ark Therapeutics Group plc ('Ark' or the 'Company') announces today that it has signed an agreement with the private Finnish biotechnology company, Oy Lx Therapies Ltd ('Lx Therapies'), to produce Vascular Endothelial Growth Factor C in an Adenoviral Vector (Ad VEGF-C). Under the agreement, Ark will undertake all manufacturing and filling activities for pre-clinical use and future clinical production of Ad VEGF-C and make available certain regulatory documentation to... Wed, 01 Jul 2009 14:04:00 GMT http://www.tvm-capital.com/pages/news/2009/ark0701.php http://www.tvm-capital.com/pages/news/2009/ark0701.php http://feedproxy.google.com/~r/tvmcapitalallnews/~3/HuezRxBPigc/evo0629.php Jun 29, 2009 Evotec Announces the Successful Completion of the First Phase I Study with EVT 401, an Oral P2X7 Receptor Antagonist - Very Good Safety Profile and Confirmed "On Target Activity" Hamburg, Germany - - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401. EVT 401 is a small molecule drug candidate and a potentially novel approach to orally treat inflammatory conditions s... Mon, 29 Jun 2009 14:27:00 GMT http://www.tvm-capital.com/pages/news/2009/evo0629.php http://www.tvm-capital.com/pages/news/2009/evo0629.php http://feedproxy.google.com/~r/tvmcapitalallnews/~3/dscotHhxziA/alf0626.php syngenio enhances its portfolio in the field of process consulting and architecture management Customers benefit from efficient solution to plan and govern complex IT organizations Munich, 26th June 2009 � syngenio, the independent IT consulting and service provider and alfabet, a leading software vendor for strategic IT planning and management, today announced their formation of a strategic partnership. syngenio joins alfabet�s global partner network as a consulting partner and thus... Fri, 26 Jun 2009 13:55:00 GMT http://www.tvm-capital.com/pages/news/2009/alf0626.php http://www.tvm-capital.com/pages/news/2009/alf0626.php http://feedproxy.google.com/~r/tvmcapitalallnews/~3/gvwxaTux41E/tra0625.php Company Also Receives Patent Covering ARIKACE for Once-Daily Treatment of Pseudomonas Lung Infections MONMOUTH JUNCTION, NJ, June 25, 2009 � Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, has provided a $2.2 million award to Transave Inc., for the continued development of ARIKACE� (liposomal amikacin for inhalation), an antibiotic that aims to treat Pseudomonas lung infections in cystic fibrosis (CF) and non-CF bronchiectasis patients. ... Thu, 25 Jun 2009 14:02:00 GMT http://www.tvm-capital.com/pages/news/2009/tra0625.php CFhttp://www.tvm-capital.com/pages/news/2009/tra0625.php http://feedproxy.google.com/~r/tvmcapitalallnews/~3/qq_ON2hvf_U/evo0624.php - Addition of ion channel focused library and additional electrophysiology equipment to support ion channel screening and medicinal chemistry alliances Hamburg, Germany I Oxford, UK - 24th June 2009: Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC), a leading provider in the discovery and development of novel small molecule drugs, today announced the expansion of its ion channel capabilities with the addition of unique, ion channel focused libraries and additional electrophysiology... Wed, 24 Jun 2009 20:37:00 GMT http://www.tvm-capital.com/pages/news/2009/evo0624.php http://www.tvm-capital.com/pages/news/2009/evo0624.php http://feedproxy.google.com/~r/tvmcapitalallnews/~3/GLMgLlhrUzY/add0624.php Novel Approach Has Potential for Treatment of Multiple CNS Disorders Geneva, Switzerland, 24 June 2009 � Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today that its partner Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMP) has started Phase I testing of ADX71149, a metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM). This product, which has potential to treat schizophrenia, anxiety, depression and other CNS disorders, is the first PAM of any... Wed, 24 Jun 2009 20:34:00 GMT http://www.tvm-capital.com/pages/news/2009/add0624.php PAMADXNOMPhttp://www.tvm-capital.com/pages/news/2009/add0624.php http://feedproxy.google.com/~r/tvmcapitalallnews/~3/PljupIHIT3Y/gpc0623.php June 23, 2009 Martinsried/Munich (Germany) and Princeton, N.J., June 23, 2009 � GPC Biotech AG (Frankfurt Stock Exchange: GPC) announced that the shareholders� meeting today approved the adoption of the merger agreement between the Company and diagennix GmbH (to be renamed Agennix AG and converted into a stock corporation). Pursuant to the merger agreement, GPC Biotech, as transferring entity, is to be merged into Agennix AG, as absorbing entity, to which were contributed all the shares of... Tue, 23 Jun 2009 13:22:00 GMT http://www.tvm-capital.com/pages/news/2009/gpc0623.php http://www.tvm-capital.com/pages/news/2009/gpc0623.php http://feedproxy.google.com/~r/tvmcapitalallnews/~3/GQjt3h0ELv8/tvm0619.php June 19, 2009, Boston, MA � Dr. Irena Melnikova has been promoted to Principal of the TVM Capital Life Science Team in Boston. She has been a valuable addition to the Boston office due diligence and investment capabilities since joining TVM Capital in 2008. �Irena�s strong scientific knowledge has been a key asset in investment management and the evaluation of new investment opportunities,� said Dr. Helmut Sch�hsler, managing partner of TVM Capital. �We look forward to expanding her role with... Fri, 19 Jun 2009 15:48:00 GMT http://www.tvm-capital.com/pages/news/2009/tvm0619.php http://www.tvm-capital.com/pages/news/2009/tvm0619.php